title: Serum anti-müllerian hormone levels in patients with epithelial ovarian cancer.
abstract: Objectives. The aim of our study was to examine serum anti-Müllerian hormone (AMH) concentration in ovarian cancer patients in relation to clinicopathological features, such as a pathological subtype of the tumor, (FIGO) stage, grading, and overall 5-year survival. Material and Methods. We enrolled 72 epithelial ovarian cancer patients in our study, aged 45-79 years, who underwent optimal cytoreductive surgery. In all patients, serum AMH concentration was measured using a two-step sandwich type enzyme immunoassay before surgery. As a reference value for women over 45 years we accepted anti-Müllerian hormone concentration below 1 ng/mL. Results. In the whole group of patients with ovarian cancer, median serum concentration of AMH was 0.07 (0.0-0.37) ng/mL, whereas in the group of those with positive AMH values (≥0.14 ng/mL) it was 0.31 (0.15-0.73) ng/mL. No significant correlation was found between serum AMH levels and FIGO stage, histological subtype, or grading (P > 0.05). The analysis of five-year survival rate related to AMH levels showed no statistically significant differences. There were no differences in survival rates between patients with positive or negative serum AMH levels. Conclusion. Measurement of serum anti-Müllerian hormone levels was not useful in predicting clinicopathological features and survival in patients with ovarian cancer.
authors: Department of Obstetrics and Gynecology, L. Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, Ulica Ujejskiego 75, 85-168 Bydgoszcz, Poland.
authors: Pawel
authors: P
authors: Walentowicz
authors: Pawel
authors: P
authors: Sadlecki
authors: Magdalena
authors: M
authors: Krintus
authors: Grazyna
authors: G
authors: Sypniewska
authors: Aneta
authors: A
authors: Mankowska-Cyl
authors: Marek
authors: M
authors: Grabiec
authors: Malgorzata
authors: M
authors: Walentowicz-Sadlecka
references: Int J Endocrinol. 2013;2013:637919
references: 23509455
references: Hum Reprod Update. 2010 Mar-Apr;16(2):113-30
references: 19793843
references: N Engl J Med. 1992 Feb 13;326(7):466-71
references: 1732773
references: Hum Reprod. 2003 Feb;18(2):323-7
references: 12571168
references: Fertil Steril. 2006 May;85(5):1541-3
references: 16566934
references: Hum Pathol. 2000 Oct;31(10):1202-8
references: 11070112
references: J Clin Endocrinol Metab. 1996 Feb;81(2):571-6
references: 8636269
references: Clin Cancer Res. 1999 Nov;5(11):3488-99
references: 10589763
references: Clin Biochem. 2012 Dec;45(18):1568-72
references: 22884489
references: J Clin Endocrinol Metab. 2012 Jun;97(6):2059-67
references: 22472563
references: Clin Cancer Res. 2002 Aug;8(8):2640-6
references: 12171896
references: Menopause. 2004 Nov-Dec;11(6 Pt 1):601-6
references: 15545787
references: Fertil Steril. 2002 Feb;77(2):357-62
references: 11821097
references: Eur J Endocrinol. 1996 Aug;135(2):144-52
references: 8810722
references: Fertil Steril. 2009 Jan;91(1):226-30
references: 18249391
references: Fertil Steril. 2000 Apr;73(4):859-61
references: 10731554
references: Cell. 1994 Nov 4;79(3):415-25
references: 7954809
references: Hum Reprod. 2008 Mar;23(3):674-8
references: 18216040
references: CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29
references: 22237781
references: Lancet Oncol. 2008 Dec;9(12):1191-7
references: 19038766
references: Hematology. 2007 Apr;12(2):141-7
references: 17454195
references: Hum Reprod. 2006 Dec;21(12):3103-7
references: 16923748
references: Curr Opin Obstet Gynecol. 2010 Jun;22(3):193-201
references: 20407372
references: Endocrinology. 1995 Nov;136(11):4951-62
references: 7588229
references: Clin Biochem. 2011 Jul;44(10-11):884-8
references: 21549107
references: Fertil Steril. 2011 Feb;95(2):747-50
references: 21074758
references: Fertil Steril. 2009 Nov;92(5):1794-8
references: 19539911